$587 Million is the total value of BVF INC/IL's 30 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCXI | Sell | CHEMOCENTRYX INC | $54,090,000 | +18.0% | 6,677,722 | -11.8% | 9.22% | -0.4% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $42,341,000 | +0.0% | 2,232,014 | -1.0% | 7.22% | -15.6% |
| VTAE | Sell | VITAE PHARMACEUTICALS INC | $37,310,000 | +42.6% | 2,061,325 | -13.2% | 6.36% | +20.3% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $34,028,000 | -33.0% | 2,935,975 | -39.8% | 5.80% | -43.5% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $28,201,000 | -36.1% | 6,682,711 | -31.0% | 4.81% | -46.1% |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $22,347,000 | -2.1% | 991,433 | -28.0% | 3.81% | -17.4% |
| Sell | EXELIXIS INCnote 4.250% 8/1 | $22,187,000 | -32.8% | 18,842,778 | -30.8% | 3.78% | -43.3% | |
| LOXO | Sell | LOXO ONCOLOGY INC | $20,230,000 | -24.4% | 711,067 | -53.6% | 3.45% | -36.2% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $3,039,000 | -36.1% | 970,948 | -4.9% | 0.52% | -46.1% |
| GBIM | Sell | GLOBEIMMUNE INC | $2,539,000 | +43.4% | 657,653 | -3.1% | 0.43% | +20.9% |
| MSTX | Sell | MAST THERAPEUTICS INC | $1,554,000 | -47.5% | 3,696,961 | -27.6% | 0.26% | -55.7% |
| CALA | Sell | CALITHERA BIOSCIENCES INC | $1,286,000 | -48.1% | 167,900 | -63.2% | 0.22% | -56.3% |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -41,600 | -100.0% | -0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.